Earnings summaries and quarterly performance for BLDE.
Executive leadership at BLDE.
Board of directors at BLDE.
Research analysts who have asked questions during BLDE earnings calls.
Jason Helfstein
Oppenheimer & Co. Inc.
3 questions for BLDE
Also covers: ANGI, CART, COMP +23 more
Benjamin Klieve
Lake Street Capital Markets
2 questions for BLDE
Also covers: ANDE, AVD, AVO +10 more
Jon Hickman
Ladenburg Thalmann
2 questions for BLDE
Also covers: BYRN, CLSK, CREX +9 more
LL
Laura Lee
Deutsche Bank
2 questions for BLDE
Also covers: EH, LOT, VTOL
MK
Mahima Kakani
JPMorgan Chase & Co.
2 questions for BLDE
Also covers: ACHR, CHPT, EVGO +1 more
Ben Klieve
Lake Street Capital Markets
1 question for BLDE
Also covers: ANDE, AVD, AVO +13 more
BP
Bill Peterson
JPMorgan Chase & Co.
1 question for BLDE
Also covers: AA, ACHR, CHPT +11 more
LL
Laura Li
Deutsche Bank
1 question for BLDE
Also covers: EH, LOT
WP
William Peterson
JPMorgan Chase & Co.
1 question for BLDE
Also covers: AA, ACHR, CHPT +14 more
XY
Xin Yu
Deutsche Bank
1 question for BLDE
Also covers: ACHR, ADNT, ALV +12 more
Recent press releases and 8-K filings for BLDE.
Strata Outlines Growth Strategy and Financial Outlook at 2025 Investor Day
BLDE
Guidance Update
M&A
New Projects/Investments
- Strata (formerly Blade) rebranded to Strata Critical Medical (SRTA) in August 2025, divesting its passenger business to Joby for up to $125 million to focus entirely on healthcare.
- The company provided 2026 financial guidance, projecting revenue between $255 million and $270 million and adjusted EBITDA between $28 million and $32 million.
- For the medium term (2027-2029), Strata expects low double-digit organic revenue growth, adjusted EBITDA margins to reach 13% by 2029, and adjusted EBITDA to organically double by 2029.
- Strata plans to deploy approximately $200 million in capital for acquisitions over the 2027-2029 period, targeting mid-single-digit EBITDA multiples, which could significantly boost EBITDA beyond organic growth.
Nov 17, 2025, 7:00 PM
Strata Outlines Strategic Shift and Financial Outlook at Investor Day 2025
BLDE
M&A
Guidance Update
New Projects/Investments
- Strata (formerly Blade) has rebranded to Strata Critical Medical (ticker SRTA) and is now a pure-play provider of logistics and critical services in the organ transplant sector, following the August 2025 divestiture of its passenger business to Joby for up to $125 million.
- The company reported its medical segment revenue grew at over a 40% organic CAGR over the last five years, with adjusted EBITDA margins reaching the mid-14% range in 2025.
- For 2026, Strata provided guidance for revenue between $255 million and $270 million, adjusted EBITDA between $28 million and $32 million, and free cash flow (before aircraft or engine acquisitions) between $15 million and $22 million.
- Strata outlined a medium-term value creation framework for 2027-2029, projecting low double-digit organic revenue growth, adjusted EBITDA margins reaching 13% by 2029, and approximately $200 million of cash available for deployment for potential acquisitions.
Nov 17, 2025, 7:00 PM
Strata Outlines Growth Strategy and Financial Targets at 2025 Investor Day
BLDE
Guidance Update
New Projects/Investments
M&A
- Strata (formerly Blade) has rebranded and is now 100% focused on healthcare, specifically organ transplant logistics and clinical services, following the August 2025 sale of its passenger business to Joby for proceeds of up to $125 million.
- The company provided 2026 financial guidance, projecting revenue between $255 million and $270 million, adjusted EBITDA between $28 million and $32 million, and free cash flow before aircraft or engine acquisitions between $15 million and $22 million.
- For the medium term (2027-2029), Strata expects low double-digit organic revenue growth, adjusted EBITDA margins reaching 13% by 2029, and anticipates organically doubling adjusted EBITDA by 2029.
- Strata plans to deploy approximately $200 million over the next four years for acquisitions in the fragmented transplant ecosystem, which could add an additional $25 million of EBITDA if 75% is deployed at target mid-single-digit multiples.
- Key growth drivers include expanding market share in air (30%) and ground (15%) logistics, increased penetration of Normothermic Regional Perfusion (NRP), and leveraging its owned fleet of 10 Hawker 800 aircraft purchased in 2024 for margin expansion.
Nov 17, 2025, 7:00 PM
Strata Critical Medical Reports Strong Q3 2025 Results and Raises Full-Year Revenue Guidance
BLDE
Earnings
Guidance Update
M&A
- Strata Critical Medical, formerly BLDE, reported strong Q3 2025 results, with year-over-year revenue growth accelerating to 29% excluding Keystone, and medical segment-adjusted EBITDA growing 80% year-over-year, leading to a 15.1% margin.
- The company completed two significant transactions during the quarter: the divestiture of its passenger business and the acquisition of Keystone Perfusion, which contributed $2.8 million in revenue for a half-month.
- Strata generated approximately $2 million in free cash flow from continuing operations in Q3 2025 and ended the quarter with no debt and approximately $76 million in cash and short-term investments.
- Management raised its 2025 revenue guidance range to $185 million-$195 million while reaffirming adjusted EBITDA guidance at $13 million-$14 million.
Nov 10, 2025, 1:00 PM
Strata Critical Medical Reports Strong Q3 2025 Results and Raises Revenue Guidance
BLDE
Earnings
M&A
Guidance Update
- Strata Critical Medical (formerly BLDE) completed significant strategic transactions in Q3 2025, including the divestiture of its passenger business and the acquisition of Keystone Perfusion, and rebranded to reflect its sharpened focus on healthcare.
- In Q3 2025, revenue increased 36.7% year-over-year to $49.3 million, with revenue excluding Keystone growing 29%. The medical segment-adjusted EBITDA margin, excluding Keystone, rose to 15.1%.
- The company generated approximately $2 million of free cash flow from continuing operations in Q3 2025 and ended the quarter with no debt and $76 million of cash and short-term investments.
- Strata raised its 2025 revenue guidance range to $185 million-$195 million and reaffirmed its adjusted EBITDA guidance range of $13 million-$14 million.
Nov 10, 2025, 1:00 PM
Strata Critical Medical Reports Strong Q3 2025 Results, Raises Revenue Guidance
BLDE
Earnings
Guidance Update
M&A
- Strata Critical Medical (formerly BLDE) reported strong Q3 2025 results, with total revenue increasing 36.7% year-over-year to $49.3 million, and revenue excluding the Keystone acquisition growing 29%.
- The company achieved significant profit improvement, with medical segment-adjusted EBITDA (excluding Keystone) growing 80% year-over-year, resulting in a 15.1% margin in Q3 2025.
- Strata generated approximately $2 million in free cash flow from continuing operations and ended Q3 2025 with $76 million in cash and no debt.
- The company raised its 2025 revenue guidance to $185 million - $195 million while reaffirming its adjusted EBITDA guidance of $13 million - $14 million.
- Strategic initiatives included the divestiture of its passenger business, the acquisition of Keystone Perfusion, and a rebranding to reflect its sharpened focus on healthcare.
Nov 10, 2025, 1:00 PM
Strata Critical Medical Completes Passenger Business Sale, Rebrands, and Updates Guidance
BLDE
M&A
Guidance Update
Management Change
- Blade Air Mobility, Inc. has rebranded to Strata Critical Medical, Inc., with its common stock and public warrants now trading under SRTA and SRTAW as of August 29, 2025.
- The company completed the sale of its Passenger business to Joby Aero, Inc. on August 29, 2025, for an initial consideration of approximately $76.0 million in Joby Aviation's common stock, with potential for up to $45.0 million in additional consideration.
- This divestiture marks a strategic shift, with the company now solely focused on organ logistics and other medical services.
- The company updated its full-year 2025 financial guidance to reflect the divestiture, projecting revenue of $160-170 million and double-digit Adjusted EBITDA.
- Melissa Tomkiel and William Heyburn were appointed as co-Chief Executive Officers and joined the Board of Directors, effective August 28, 2025.
Aug 29, 2025, 12:31 PM
Blade Air Mobility to Rebrand as Strata Critical Medical
BLDE
New Projects/Investments
M&A
- Blade Air Mobility, Inc. will rebrand as Strata Critical Medical, Inc. effective August 28, 2025, to focus exclusively on mission-critical logistics and medical services.
- Starting August 29, 2025, the company's stock will trade on the Nasdaq Capital Market under the new ticker symbol "SRTA".
- This strategic shift follows the sale of Blade's Passenger business to Joby Aviation, marking an exit from passenger air transport to concentrate on medical logistics, including organ transplants.
- There will be no changes to CUSIP numbers or securityholder rights, and no action is required from securityholders.
Aug 27, 2025, 12:20 PM
Quarterly earnings call transcripts for BLDE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more